Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Chad Z. Tang, James William Welsh, Patricia M. de Groot et al. · Clinical Cancer Research · 2016
Abstract Purpose: Little prospective data are available on clinical outcomes and immune correlates from combination radiation and immunotherapy. We conducted a phase I trial (NCT02239900) testing stereotactic ablative radiotherapy (SABR) with ipilimumab. Experimental Design: SABR was given either concurrently (1 day after the first dose) or sequentially (1 week after the second dose) with ipilimumab (3 mg/kg every 3 weeks for 4 doses) to five treatment groups: concurrent 50 Gy (in 4 fractions) to liver; sequential 50 Gy (in 4 fractions) to liver; concurrent 50 Gy (in 4 fractions) to lung; sequential 50 Gy (in 4 fractions) to lung; and sequential 60 Gy (in 10 fractions) to lung or liver. MTD was determined with a 3 + 3 dose de-escalation design. Immune marker expression was assessed by flow cytometry. Results: Among 35 patients who initiated ipilimumab, 2 experienced dose-limiting toxicity and 12 (34%) grade 3 toxicity. Response outside the radiation field was assessable in 31 patients. Three patients (10%) exhibited partial response and 7 (23%) experienced clinical benefit (defined as partial response or stable disease lasting ≥6 months). Clinical benefit was associated with increases in peripheral CD8+ T cells, CD8+/CD4+ T-cell ratio, and proportion of CD8+ T cells expressing 4-1BB and PD1. Liver (vs. lung) irradiation produced greater T-cell activation, reflected as increases in the proportions of peripheral T cells expressing ICOS, GITR, and 4-1BB. Conclusions: Combining SABR and ipilimumab was safe with signs of efficacy, peripheral T-cell markers may predict clinical benefit, and systemic immune activation was greater after liver irradiation. Clin Cancer Res; 23(6); 1388–96. ©2016 AACR.
Cited by 321 works. doi:10.1158/1078-0432.ccr-16-1432
Authors
- Chad Z. Tang
- James William Welsh
- Patricia M. de Groot
- Erminia Massarelli
- Joe Yujiao Chang
- Kenneth R. Hess
- Sreyashi Basu
- Michael A. Curran
- Maria E. Cabanillas
- Vivek Subbiah
- Siqing Fu
- Apostolia Maria Tsimberidou
- Daniel D. Karp
- Daniel Richard Gomez
- Adi K. Diab
- Ritsuko U Komaki
- John Victor Heymach
- Padmanee Sharma
- Aung Naing
- David S. Hong
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma